Commentary: Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management

Yifan Deng, Shuai Han, Xiaohui Gao, Yang Liu, Jiapei GaoFrontiers in Oncology 2024 · DOI

Introduction

Chronic Neutrophilic Leukemia (CNL) is a rare myeloproliferative neoplasm characterized by the sustained overproduction of mature neutrophils. A significant clinical challenge arises when CNL presents alongside plasma cell disorders (PCD), such as Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance (MGUS). This commentary, originally published in Frontiers in Oncology, examines the diagnostic boundaries and genetic profiles of these overlapping conditions.

The Diagnostic Challenge: Leukemia vs. Leukemoid Reaction

Distinguishing "true" CNL from a reactive "leukemoid reaction"—a non-malignant spike in neutrophils triggered by an underlying plasma cell disorder—is a historical hurdle in hematology. Before the integration of molecular markers, CNL was often a diagnosis of exclusion. The 2016 WHO diagnostic criteria revolutionized this process by emphasizing myeloid clonality, primarily through the identification of the CSF3R T618I mutation.

Methodology and Data Synthesis

The authors conducted a comprehensive review of literature from PubMed and CNKI databases, identifying 16 cases of CNL associated with PCD (CNL-PCD) that strictly adhered to the 2016 WHO criteria. This cohort was compared against established datasets for isolated CNL and broader myeloproliferative neoplasm (MPN) studies to evaluate genetic divergence and clinical outcomes.

Genetic Landscape and Key Insights

The study highlights several critical findings regarding the genetic architecture of CNL-PCD:

  • CSF3R Mutation Frequency: In the 16 cases analyzed, the CSF3R mutation rate was 62.5%. This is notably lower than the frequency observed in isolated CNL, suggesting that CNL-PCD may involve distinct driver mutations or a shared genetic susceptibility between myeloid and lymphoid lineages.
  • Secondary Mutations: Mutations in SETBP1 and ASXL1 were also identified, both of which are typically associated with a more aggressive disease course and poorer prognosis.
  • Pathophysiological Links: The co-occurrence suggests a potential "inflammatory bridge," where chronic inflammation from myeloid leukemia promotes B-cell proliferation, or both conditions arise from a common progenitor cell.

Clinical Outcomes and Management

The median survival for the CNL-PCD cohort was approximately 22 months, consistent with general CNL populations. However, the data suggests that patients with MGUS-associated CNL might experience slightly better outcomes than those with isolated CNL.

Current management strategies include:

  • Hydroxyurea: Remains the primary frontline therapy, effective in 75% of cases for symptom management.
  • Ruxolitinib: As a JAK inhibitor, it offers a targeted approach for CSF3R-mutated cases, though its long-term disease-modifying capability remains limited.
  • Allo-HSCT: Allogeneic hematopoietic stem cell transplantation remains the only curative path, with a one-year survival rate of 69%.

Limitations and Future Directions

The rarity of CNL limits the sample size, making broad statistical generalizations difficult. The authors advocate for the routine use of Next-Generation Sequencing (NGS) to clarify the clonal relationships in these overlap cases. Refining WHO criteria to specifically address the intersection of myeloid and plasma cell disorders will be essential for optimizing patient-specific treatment protocols.

Summary updated

Abstract

Commentary: Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management
BibTeX
@inproceedings{deng2024commentary,
  author = {Yifan Deng and Shuai Han and Xiaohui Gao and Yang Liu and Jiapei Gao},
  title = {{Commentary: Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1360791},
}
Figure